-
10:18:12 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

OPGN Stock News

06/22/22 8:00 AM
Nasdaq : OPGN
covid-19
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of pathogens by Unyvero HPN Additional pathogens detected by Unyvero HPN confirmed in many instances by culture positivity for the same microorganism in
RHEA-AI
neutral
05/26/22 7:30 AM
Nasdaq : OPGN
clinical trial
OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% Unyvero results
RHEA-AI
negative
04/06/22 7:30 AM
Nasdaq : OPGN
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
Extended existing master services agreement with Sandoz, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025 Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing
RHEA-AI
neutral